Forbes Publish Date: Nov 22, 2022 Harvard trained surgeon and big data entrepreneur Dr. Richard Gliklich has been working to improve the management of chronic conditions by organising, analysing and applying health outcomes data since 1999. Currently he is the founder and CEO of OM1 (pronounced Ohm-one). The company is a health outcomes and registries[…]
HealthEconomics.com – A Scientist.com Company Publish Date: August 26th, 2022 Multiple sclerosis (MS) is a chronic illness in which the body’s immune system attacks myelin, the substance that surrounds and protects the nerve fibers of the central nervous system. The result is a disabling disease that causes damage to the brain and spinal cord[…]
Gastrointestinal and metabolic disorders are highly prevalent and result in reduced quality of life for many patients. Treatments are aimed at reducing symptoms and preventing complications and progression. More research is needed to better understand natural history and progression, treatment effectiveness, and outcomes. Register here Linked real-world data (RWD) and machine learning (ML) applications provide[…]
Wed, Aug 18, 2021 2:00 PM – 3:00 PM EDT Presenter: Richard Gliklich, MD, CEO, OM1 Register >> Automated, clinical ‘data networks’ are transforming the research paradigm. This webinar explores: – How do multi-purpose, ‘reusable’ data networks differ from the traditional research model, in particular for real-world evidence and patient registries? – How are data[…]
BOSTON, July 16, 2021 /PRNewswire/ — OM1, a health technology company focused on real-world outcomes for chronic conditions, today announced an $85 million financing led by D1 Capital Partners, Kaiser Permanente, and Breyer Capital, with participation from existing investors, including General Catalyst (GC), Polaris Partners, Scale Venture Partners, 7wire Ventures, and Glikvest. OM1 partners with providers, medical societies, payers, and[…]
